Clinical studies recruiting near Fairfax

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · NEXT Virginia · Erasca, Inc. · NCT06983743 A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Phase 1 · Next Virginia · Johnson & Johnson Enterprise Innovation Inc. · NCT06116786 Genome Transplant Dynamics
Phase N/A · National Heart, Lung, and Blood Institute (NHLBI) · NCT02423070 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Inova Schar Cancer Institute ( Site 0015) · Merck Sharp & Dohme LLC · NCT06136559 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · NEXT Oncology Virginia · Avacta Life Sciences Ltd · NCT07454642 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Inova Schar Cancer Institute · National Cancer Institute (NCI) · NCT05564390 A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Phase 3 · Virginia Cancer Specialists PC · BioNTech SE · NCT07365995 Study of XB010 in Subjects With Solid Tumors
Phase 1 · Inova Schar Cancer · Exelixis · NCT06545331 A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · NEXT Oncology Virginia · IDEAYA Biosciences · NCT07174583 A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · NEXT Virginia · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762 PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
Phase 3 · Inova Health System · Duke University · NCT07232069 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · Virginia Cancer Specialists · Verastem, Inc. · NCT07644559 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · NEXT Virginia · Revolution Medicines, Inc. · NCT07397338 A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced
Phase 1 · NEXT Virginia · Kumquat Biosciences Inc. · NCT06994806 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in
Phase 1 · NEXT Oncology · Cartography Biosciences · NCT07321106 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Inova Cardiology - Fairfax · Amgen · NCT07037433 Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · Virginia Cancer Specialists, PC · Pfizer · NCT07421700 A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Phase 1 · NEXT Virginia · PAQ Therapeutics, Inc. · NCT06797336 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Clinical Study Site · Summit Therapeutics · NCT07228832 A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Phase 1 · NEXT Virginia · Peel Therapeutics Inc · NCT05329103 A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/Phase 2 · Virginia Cancer Specialist, PC · Deciphera Pharmaceuticals, LLC · NCT05957367 Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Phase 1/Phase 2 · NEXT, Virginia · MBrace Therapeutics · NCT07145255 A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · Site 1002 · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07407933 A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Phase 1/Phase 2 · Site-102 · Biohaven Therapeutics Ltd. · NCT06384807 A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Phase N/A · Lysosomal & Rare Disorder Research & Treatment Center (LRDRT · Chiesi Farmaceutici S.p.A. · NCT06663358 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 2137 · Turning Point Therapeutics, Inc. · NCT03093116 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid T
Phase 1 · NEXT Virginia · Vividion Therapeutics, Inc. · NCT06804824 First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · Research Site · Plexium, Inc. · NCT07284186 A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Phase N/A · The Retina Group of Washington · Astellas Pharma Global Development, Inc. · NCT06779773 A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · NEXT Virginia ( Site 0054) · Merck Sharp & Dohme LLC · NCT07247110

Look up another city

Look up another condition